RayKnowChina Research Map
Shortlist0

Not yet recruitingNeuromyelitis optica spectrum disorderPhase 2

Registered title, quoted from ClinicalTrials.gov

Efficacy and Safety of Low-Dose IL-2 in Neuromyelitis Optica Spectrum Disorder

An open trial on neuromyelitis optica spectrum disorder, registered on ClinicalTrials.gov. Led by Peking University People's Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorPeking University People's Hospital北京大学人民医院BeijingHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07809724, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 74 years; sex: all

    Registered eligibility fields

  2. Expanded Disability Status Scale (EDSS) score between 0 and 6.5.

    Inclusion criterion 3

  3. White blood cell count <3000/ml, lymphocyte count <1000/ml, platelet count <150,000/ml.

    Exclusion criterion 9

  4. For women of childbearing potential, contraception must be used for more than 2 weeks after meeting the inclusion criteria, and HCG must be negative at the time of enrollment.

    Inclusion criterion 4

    Pregnancy or breastfeeding.

    Exclusion criterion 3

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; earlier treatment; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07809724, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age: 18 to 74 years, inclusive at the time of informed consent.
  • Diagnosed with NMOSD according to the 2015 international consensus diagnostic criteria for NMOSD.
  • Expanded Disability Status Scale (EDSS) score between 0 and 6.5.
  • For women of childbearing potential, contraception must be used for more than 2 weeks after meeting the inclusion criteria, and HCG must be negative at the time of enrollment.
  • Able to provide written informed consent and demonstrate the ability and willingness to comply with the study protocol requirements.

Exclusion Criteria:

  • Any prior history of receiving whole-body irradiation or bone marrow transplantation.
  • Any treatment with investigational drugs within 3 months prior to baseline.
  • Pregnancy or breastfeeding.
  • Any surgical procedure within 4 weeks prior to baseline (except minor surgeries).
  • Evidence of other demyelinating diseases or progressive multifocal leukoencephalopathy (PML).
  • Evidence of severe uncontrolled comorbidities that may hinder participation.
  • Other neurological disorders, hematological / hematopoietic disorders, congenital/acquired severe immunodeficiencies.
  • Heart failure (≥NYHA Class III), renal insufficiency, liver insufficiency, or respiratory failure.
  • White blood cell count <3000/ml, lymphocyte count <1000/ml, platelet count <150,000/ml.
  • Evidence of chronic active hepatitis B or C.
  • Substance abuse or alcoholism history within 1 year prior to baseline.
  • Evidence of active tuberculosis (excluding participants undergoing chemoprophylaxis for latent tuberculosis infection).
  • Intolerance to IL-2: hypersensitivity reactions to the active substance or any of its excipients (e.g. shock, allergic reactions).
  • Active suicidal ideation within the past 6 months before screening, or a history of suicide attempts within the past 3 years.

Quoted from ClinicalTrials.gov, NCT07809724, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07809724, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07809724